Can nutrient supplements deliver iron better? small study aims to find out
NCT ID NCT06870201
First seen Jun 25, 2026 · Last updated Aug 04, 2026 · Updated 3 times
Summary
This pilot study looks at how well young children absorb iron from special nutrient supplements. Researchers will give 30 children in Kenya (ages 1-3) a supplement with a harmless iron tracer, then measure iron levels in their blood two weeks later. Half the children are healthy, and half are undernourished. The goal is to understand if these supplements can effectively deliver iron to fight anemia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Lipid-based nutrient supplement with stable iron isotope
- What this could lead to
- If successful, this could help design better iron-fortified supplements to fight anemia and undernutrition in children.
- What could go wrong
- This is a small pilot study with only 30 children, so results may not apply broadly. It measures iron absorption, not health outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Msambweni County Referral Hospital
Msambweni, Kenya
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test